My guess is the accusations could be made about any cannabis company in terms of valuation if you ignore the growth rates.
They are comparing Organagram to Cronos to get to their $3.50 valuation, but Cronos' growth rate is 4X Organagram's.
It smells like a scam. The three regular staff on CNBC who interviewed him clearly had doubts that he could produce the details to support his claims. We'll see. jmo
Trading platforms have to maintain their integrity for people to trust them enough to trade securities. So they screen and monitor the companies they list and the trading practices they allow. Everyone knows that.
Andrew Left's practices should be federally investigated if for no other reason than to show the system is doing it's job in providing basic safeguards to prevent fraud. jmo